[go: up one dir, main page]

FR3121360B1 - Formulation pour la délivrance d’ARN messager - Google Patents

Formulation pour la délivrance d’ARN messager Download PDF

Info

Publication number
FR3121360B1
FR3121360B1 FR2103254A FR2103254A FR3121360B1 FR 3121360 B1 FR3121360 B1 FR 3121360B1 FR 2103254 A FR2103254 A FR 2103254A FR 2103254 A FR2103254 A FR 2103254A FR 3121360 B1 FR3121360 B1 FR 3121360B1
Authority
FR
France
Prior art keywords
formulation
messenger rna
delivery
lipid nanoparticles
nanoemulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2103254A
Other languages
English (en)
Other versions
FR3121360A1 (fr
Inventor
Y Garcia Fabrice Navarro
Patrice Marche
Adrien Nougarede
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Institut National de la Sante et de la Recherche Medicale INSERM
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA, Institut National de la Sante et de la Recherche Medicale INSERM, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Commissariat a lEnergie Atomique CEA
Priority to FR2103254A priority Critical patent/FR3121360B1/fr
Priority to PCT/EP2022/058466 priority patent/WO2022207736A1/fr
Priority to EP22719866.0A priority patent/EP4312989A1/fr
Publication of FR3121360A1 publication Critical patent/FR3121360A1/fr
Application granted granted Critical
Publication of FR3121360B1 publication Critical patent/FR3121360B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulation pour la délivrance d’ARN messager L’invention concerne une formulation sous forme de nanoémulsion, comprenant une phase aqueuse continue et au moins une phase dispersée sous forme de nanoparticules lipidiques dans laquelle au moins un ARN messager est complexé à la surface des nanoparticules lipidiques, son procédé de préparation et ses utilisations pour la prévention et/ou le traitement d’une maladie. Figure pour l'abrégé : 1
FR2103254A 2021-03-30 2021-03-30 Formulation pour la délivrance d’ARN messager Active FR3121360B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR2103254A FR3121360B1 (fr) 2021-03-30 2021-03-30 Formulation pour la délivrance d’ARN messager
PCT/EP2022/058466 WO2022207736A1 (fr) 2021-03-30 2022-03-30 Formulation pour la délivrance d'arn messager
EP22719866.0A EP4312989A1 (fr) 2021-03-30 2022-03-30 Formulation pour la délivrance d'arn messager

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2103254A FR3121360B1 (fr) 2021-03-30 2021-03-30 Formulation pour la délivrance d’ARN messager
FR2103254 2021-03-30

Publications (2)

Publication Number Publication Date
FR3121360A1 FR3121360A1 (fr) 2022-10-07
FR3121360B1 true FR3121360B1 (fr) 2024-05-31

Family

ID=75850360

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2103254A Active FR3121360B1 (fr) 2021-03-30 2021-03-30 Formulation pour la délivrance d’ARN messager

Country Status (3)

Country Link
EP (1) EP4312989A1 (fr)
FR (1) FR3121360B1 (fr)
WO (1) WO2022207736A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9877919B2 (en) * 2012-03-29 2018-01-30 Translate Bio, Inc. Lipid-derived neutral nanoparticles
FR2994849B1 (fr) 2012-08-30 2015-01-02 Commissariat Energie Atomique Formulation pour la delivrance de sequences nucleotidiques susceptibles de moduler des mecanismes endogenes d'arn interferents

Also Published As

Publication number Publication date
EP4312989A1 (fr) 2024-02-07
FR3121360A1 (fr) 2022-10-07
WO2022207736A1 (fr) 2022-10-06

Similar Documents

Publication Publication Date Title
EP3548091B1 (fr) Préparation de complexes solides de cyclodextrine permettant une administration de substance pharmaceutique active ophtalmique
Aly et al. Common superficial fungal infections in patients with AIDS
Mehta et al. Targeting KRAS mutant lung cancer cells with siRNA-loaded bovine serum albumin nanoparticles
Salem et al. Liposomal flucytosine capped with gold nanoparticle formulations for improved ocular delivery
Svetlichny et al. Solid lipid nanoparticles containing copaiba oil and allantoin: development and role of nanoencapsulation on the antifungal activity
HUP0102039A2 (hu) Albuminnal stabilizált paclitaxel alkalmazása tömör tumorok kezelésére szolgáló gyógyszerkészítmények előállítására, és a kapott gyógyszerkészítmények
CA3013503A1 (fr) Nanostructures appropriees pour la sequestration du cholesterol et d'autres molecules
Schnichels et al. Improved treatment options for glaucoma with brimonidine-loaded lipid DNA nanoparticles
MA37471A1 (fr) Formulation lyophilise et aqueuse d’anticorps anti-cd40
Kastantin et al. Thermodynamic and kinetic stability of DSPE-PEG (2000) micelles in the presence of bovine serum albumin
Raoult et al. Ciprofloxacin therapy for Mediterranean spotted fever
Karn-Orachai et al. Surfactant effect on the physicochemical characteristics of γ-oryanol-containing solid lipid nanoparticles
CN102573477A (zh) 治疗方法
FR3121360B1 (fr) Formulation pour la délivrance d’ARN messager
JP2022538659A (ja) 薬剤を含む水性組成物のｐＨを安定化させるための方法
EP4171507A1 (fr) Préparation de complexes de cyclodextrine solides pour l'administration de substance pharmaceutique active ophtalmique
Tonglairoum et al. Development and evaluation of N-naphthyl-N, O-succinyl chitosan micelles containing clotrimazole for oral candidiasis treatment
CA2427375A1 (fr) Composition pharmaceutique de dronedarone pour administration parenterale
JPH0741422A (ja) γ−オリザノールの水への可溶化方法
JP3889037B2 (ja) コリノイドと合成油脂または植物油脂とからなる、皮膚疾病を局所治療するための外用医薬組成物
Lamoudi et al. Fusidic acid microemulsion based on a pseudoternary phase diagram: development, characterization, and evaluation
TNSN01076A1 (fr) Associations de secretagogues d'hormone de croissance et d'antidepresseurs, et compositions les contenant
CN106852911B (zh) 一种稳定的卡巴他赛白蛋白组合物及其制备方法
JP7629392B2 (ja) グリチルリチンを含む組成物およびその化粧品および医薬品使用
Almeida et al. Nanoparticles in Ocular Drug Delivery Systems

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20221007

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5